Acute leukaemia in chronic hepatitis B patients with lamivudine therapy

International Journal of Clinical Practice

Volumn 58, Issue 11, 2004, Pages 1088-1091

  Chien, Ronh Nan ^a,b   Yeh, C T ^a   Wang, P N ^a   Kuo, M C ^a   Hsieh, S Y ^a   Shih, L S ^a   Liaw, Y F ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Acute myeloid leukaemia; Chronic hepatitis B; Lamivudine

Indexed keywords

CYTARABINE; DAUNORUBICIN; LAMIVUDINE; RETINOIC ACID; TRANSACTIVATOR PROTEIN; VIRUS DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CELL TRANSFORMATION; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; MALE; MALIGNANT TRANSFORMATION; PATIENT MONITORING; PRIORITY JOURNAL; VIRUS CARCINOGENESIS; VIRUS MUTANT; VIRUS MUTATION;

ACUTE DISEASE; ADULT; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 10444258979     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2004.00266.x     Document Type: Article

References (27)

1. Lai CL, Chien RN, Leung NWY et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
2. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
3. Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-96.
4. Liaw YF, Leung NWY, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-80.
5. Glaxo Wellcome, Data on File: Zeffix Product Monograph, P55.
6. Majluf-Cruz A, Luna-Castanos G, Trevino-Perez S et al. Lamivudine-induced prue red cell aplasia. Am J Hematol 2000; 65 189-91.
7. Liaw YF, Chien RN, Yeh CT et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
8. Ilan Y, Galun E, Nagler A et al. Sanctuary of hepatitis B virus in bone-marrow cells of patients undergoing liver transplantation. Liver Transpl Surg 1996; 2: 206-10.
9. Romet-Lemonne JL, McLane MF, Elfassi E et al. Hepatitis B virus infection in cultured human lymphoblastoid cells. Science 1983; 221: 667-9.
10. Zeldis JB, Mugishuma H, Steingerg HN et al. In vitro hepatitis B virus infection of human bone marrow cells. J Clin Invest 1986; 78: 411-7.
11. Yoffe B, Noonan CA. Hepatitis B virus, new and evolving issues. Dig Dis Sci 1992; 37: 1-9.
12. Mason A, Wick M, White H, Petrillo R. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology 1993; 18: 781-9.
13. Galun E, Ilan Y, Livni N et al. Hepatitis B virus infection associated with hematopoietic tumors. Am J Pathol 1994; 145: 1001-7.
14. Greer JP, Baer MR, Kinney MC. Acute myemogenous leukemia. In: Lee GR, Foerster J, Lukens J et al., eds. Wintrobe's Clinical Hematology, 10th edn. Baltimore: Williams & Wilkins, 1999: P2272-2319.
15. Chan CS, Chen CJ, Huang TW. Cancer registry annular report, Taiwan, ROC. 1996: P126-7.
16. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542-52.
17. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-49.
18. Spandau DF, Lee CH. Trans-activation of viral enhancers by the hepatitis B virus X protein. J Virol 1988; 62: 427-34.
19. Twu JS, Robinson WS. Hepatitis B virus X gene can transactivate heterologous viral sequences. Proc Natl Acad Sci USA 1989; 86: 2046-50.
20. Twu JS, Schloemer RH. Transcriptional transactivator function of hepatitis B virus. J Virol 1987; 61: 3448-53.
21. Wollersheim M, Debelka U, Hofschneider PH. A transactivator function encoded in the hepatitis B virus X gene is conserved in the integrated state. Oncogene 1988; 3: 545-52.
22. Kekul AS, Lauer U, Meyer M et al. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional trans-activator. Nature 1990; 343: 457-61.
23. Grasser FA, Graf T, Lipsick JS. Protein truncation is required for the activation of the c-myb proto-oncogene. Nol Cell Biol 1991; 11: 3987-96.
24. Luscher B, Eisenman RN. New light on Myc and Myb. Part II. Myb Genes Dev 1990; 4: 2235-41.
25. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31: 1318-26.
26. Lauer U, Weiss L, Hofschneider PH, Kekul AS. The hepatitis B virus pre-S/S transactivator is generated by 3′ truncations within a defined region of the S gene. J Virol 1992; 66: 5284-9.
27. Caselmann WH, Meyer M, Kekul AS et al. A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc Natl Acad Sci USA 1990; 87: 2970-4.